Natasa Janicic-Kahric
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1306845748
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,851 of the $121,276 with a category attached, or 85.6%. Novo Nordisk accounts for 67.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $31,252 and has fallen 70.3% since, to $9,292 in 2025. Among endocrinology, diabetes & metabolism clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $787.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$81K
- Dexcom, Inc.$25K
- Johnson & Johnson$10K
- Sanofi-aventis U.S. LLC$3K
- Bayer$1K
- Tandem Diabetes Care, Inc.$444
- plus $449 from 4 others
What the payments were for
- Consulting fees$9,8828%
- Speaking & faculty fees$103,85186%
- Travel & lodging$3,2413%
- Food & beverage$4,2924%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 88 | $81,448 |
| Dexcom, Inc. | 27 | $24,597 |
| Johnson & Johnson | 22 | $9,900 |
| Sanofi-aventis U.S. LLC | 3 | $3,043 |
| Bayer | 1 | $1,395 |
| Tandem Diabetes Care, Inc. | 6 | $444 |
| Insulet Corporation | 4 | $235 |
| BETA Bionics, Inc. | 1 | $102 |
| Lilly USA, LLC | 1 | $99 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$42,580
- Ozempic$33,285
- DEXCOM G6 CGM SYSTEM$10,489
- INVOKANA$9,613
- DEXCOM CGM$8,267
- DEXCOM G6 TRANSMITTER$5,605
- DISEASE STATE$3,043
- Kerendia$1,395
- iLet Bionic Pancreas$305
- t:slim X2 Insulin Pump with Control-IQ$240
- Omnipod$152
- Tresiba$125
- iLet Insulin Infusion Kit Inset$102
- iLet Insulin Infusion Kit Contact Detach$102
How this compares
$121,276 in reported general payments places this provider in the 95th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 159 | $228,643 |
| JardianceEmpagliflozin | 115 | $154,438 |
| MounjaroTirzepatide | 71 | $87,750 |
| JanuviaSitagliptin Phosphate | 81 | $82,947 |
| TrulicityDulaglutide | 43 | $60,123 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 92 | $51,930 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $29,676 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $20,505 |
| ProliaDenosumab | 11 | $19,355 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $15,904 |
| RybelsusSemaglutide | 13 | $15,833 |
| Testosterone | 45 | $14,754 |
| Novolog FlexpenInsulin Aspart | 48 | $11,454 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $9,801 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 71 | $7,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $81,448 | $249,656187 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $99 | $149,859126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
Other endocrinology, diabetes & metabolism in Washington
- Diala El-MaoucheWashington$99K
- Abbas MotazediWashington$31K
- Meeta SharmaWashington$25K
- Joseph VerbalisWashington$24K
- Mark SklarWashington$14K
- Sabyasachi SenWashington$12K
- Rui LuWashington$12K
- Qudsia HussainWashington$9K
- Jerold ShareWashington$7K
- Leonard WartofskyWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.